Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;108(2):242-247.
doi: 10.1002/cpt.1844. Epub 2020 Apr 21.

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Yin-Xiao Du  1   2   3 , Xiao-Ping Chen  1   2   3
Affiliations
Review

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection

Yin-Xiao Du et al. Clin Pharmacol Ther. 2020 Aug.

Abstract

An outbreak of 2019-nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs, such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA-dependent RNA polymerase (RdRp) inhibitors have been registered and initiated. Favipiravir, a purine nucleic acid analog and potent RdRp inhibitor approved for use in influenza, is also considered in several clinical trials. Herein, we summarized the pharmacokinetic characteristics of favipiravir and possible drug-drug interactions from the view of drug metabolism. We hope this will be helpful for the design of clinical trials for favipiravir in COVID-2019, as data regarding in vitro virus inhibition and efficacy in preclinical animal studies are still not available.

PubMed Disclaimer

Comment in

References

    1. Morse, J.S., Lalonde, T., Xu, S. & Liu, W.R. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 21, 730-738 (2020).
    1. Li, G. & Clercq, E.D. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149-150 (2020).
    1. Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov. Ther. 14, 58-60 (2020).
    1. Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 93, 449-463 (2017).
    1. Furuta, Y. et al. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49, 981-986 (2005).

Publication types

LinkOut - more resources